Drugs / OPF-310
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06575426 | Jun 2025 → Jun 2027 expected | hypoglycemia, islet cell adenomatosis, severe nonproliferative diabetic retinopathy, type 1 diabetes mellitus | Otsuka Pharmaceutical Factory, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OPF-310 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06575426 ↗ |
| Modality | Cell therapy | “Encapsulated Porcine Islet Cells for Xenotransplantation” NCT06575426 ↗ |